Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blin...

por Michael Bauer, MD, Andreas Weyland, MD, Gernot Marx, MD, Frank Bloos, MD, PhD, Stephan Weber, Dipl. Stat., Norbert Weiler, MD, Stefan Kluge, MD, Anja Diers, MD, Tim Philipp Simon, MD, Ingmar Lautenschläger, MD, Matthias Gründling, MD, Ulrich Jaschinski, MD, Philipp Simon, MD, Axel Nierhaus, MD, Onnen Moerer, MD, Lorenz Reill, MD, Achim Jörres, MD, Renfeng Guo, MD, Markus Loeffler, MD, Konrad Reinhart, MD, Niels Riedemann, MD, for the SepNet-Study Group
Publicado 2021